

Data Prepared August 26, 2008**Curriculum Vitae**Name: **JING JIE YU, M.D.**

Title: Research Associate Professor, Department of Biochemistry, School of Medicine  
 Adjunct Professor, Department of Basic Pharmaceutical Sciences, School of Pharmacy  
 Director, Molecular Medicine Core, MBRCC, Health Sciences Center

Address and Phone Number: 2312 Health Sciences South  
 Robert C. Byrd Health Sciences Center  
 West Virginia University  
 P.O. Box 9300  
 Morgantown, WV 26506-9300  
 Office: (304) 293-8661  
 FAX: (304) 293-5244  
 Email: [jyu@hsc.wvu.edu](mailto:jyu@hsc.wvu.edu)

**Education:**

<u>School</u>	<u>Degree</u>	<u>Year</u>	<u>Field</u>
Evaluation Service Inc. of New York	M.D. Equivalency	1999	First professional degree in medicine (doctor of medicine) in the United States
The Bureau of Health & Tongren Hospital, Beijing P.R. China	Attending Physician	1982	Obstetrics & Gynecology
Beijing Medical University P.R. China	M.D.	1970	Obstetrics & Gynecology

**Clinical and Research Training:**

Certificate	2002	Perkin Elmer Analytical Instruments - in Atomic Absorption Spectrometry
Certificate	2001	U.S. National Cancer Institute - in the NCI Grants Laboratory
Certificate & CME Credit	2000	U.S. National Institutes of Health FAES - in Recombinant DNA Methodology II, Bio-Trac 3
CME Credit	1999	American Society for Investigative Pathology - in Advanced Molecular Biology

Certificate	1996	PE Applied Biosystems - in Advanced Methods DNA Sequencing
CME Credit	1996	American Society for Investigative Pathology - in Concepts in Molecular Biology
CME Credit	1996	NIH NCHGR & NCBI - in Current Topics in Genome Analysis
Certificate	1992	U.S. National Institutes of Health FAES - in Polymerase Chain Reaction & Molecular Hybridization Technology
Diploma	1990	U.S. National Cancer Institute - in Cancer Prevention & Control
Certificate	1987	University of North Carolina at Chapel Hill, School of Public Health, USA - in Health Education
Certificate	1969	Beijing Hospital of Chinese Medicine - in Traditional Chinese Medicine

**Appointments:**

<u>Inclusive Dates</u>	<u>Title</u>	<u>Location</u>
7/2008-present	Adjunct Professor	Dept. Basic Pharmaceutical Sciences School of Pharmacy
7/2006-present	Research Associate Professor Coordinator, Translational studies & Director, Molecular Medicine Core	Dept. Biochemistry, School of Medicine Mary Babb Randolph Cancer Center Robert C. Byrd Health Sciences Center West Virginia University Morgantown, WV
9/2005-present	Consultant to Drug Resistance Studies	Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD

Directing research projects in the Molecular Medicine Core Facility in gene mutation screening of cancer patients in phase I and phase II clinical trials and collaborating with PIs in other Departments of WVU and NCI.

3/2005-6/2006	Research Assistant Professor Coordinator, Translational studies & Director, Molecular Medicine Core	Dept. Biochemistry & Molecular Pharmacology, School of Medicine Mary Babb Randolph Cancer Center Robert C. Byrd Health Sciences Center West Virginia University Morgantown, WV
---------------	--	---

Responsible for designing, planning and conducting research projects, and for evaluating

and interpreting experimental data in the area of gene mutation screening related to patient response to new drugs for the treatment of lung, head and neck cancers.

2/2001-2/2005	Research Assistant Professor  Coordinator, Translational studies	Dept. Biochemistry & Molecular Pharmacology, School of Medicine Mary Babb Randolph Cancer Center Robert C. Byrd Health Sciences Center West Virginia University Morgantown, WV
---------------	--	--

Responsible for coordinating laboratory studies carried out in support of translational projects at the Cancer Center. Investigating genetic mechanisms relating to development of various cancers and response to treatment.

1991-2001	Adjunct Associate Professor	Department of Population Dynamics School of Hygiene and Public Health The Johns Hopkins University Baltimore, MD
-----------	-----------------------------	---

2/2000-1/2001	GS-12/Biologist	Medical Ovarian Cancer Section Medicine Branch, Division of Clinical Sciences, National Cancer Institute National Institutes of Health, Bethesda, MD
---------------	-----------------	--

Responsible for designing, planning and conducting research projects, and for evaluating and interpreting experimental data in the area of molecular pharmacology relating to human ovarian cancer.

3/1999-1/2000	GS-11/Biologist	Medical Ovarian Cancer Section Medicine Branch, Division of Clinical Sciences, National Cancer Institute National Institutes of Health, Bethesda, MD
---------------	-----------------	--

Responsible for designing, planning and conducting research projects, and for evaluating and interpreting experimental data in the area of molecular and cellular biology relating to human ovarian cancer.

7/1998-2/1999	Molecular Biologist	Clinical Pharmacokinetics Unit, Cellular and Clinical Pharmacology Section Developmental Therapeutics Department Medicine Branch, Division of Clinical Sciences, NCI, NIH, Bethesda, MD
---------------	---------------------	---

Developed an optimal automated technique of DNA sequencing and trained staff for a polymorphism study to assess the importance of a trinucleotide repeat in the androgen receptor.

6/1992-6/1998	Staff Fellow	Medical Ovarian Cancer Section, Medicine
---------------	--------------	--

Branch, Division of Clinical Sciences  
National Cancer Institute, National Institutes  
of Health, Bethesda, MD

Supervised up to 9 laboratory personnel. Conducted studies of the subcellular mechanism of action of the anti-cancer drug taxol, as well as studies of the interactions between taxol and DNA-damaging agents such as cisplatin. Also investigated the molecular mechanisms of the relationship between nucleotide sequences, gene expression of NER and chemotherapeutic response in human ovarian cancer tumor tissues.

8/1988-5/1992	Consultant to Smoking, Tobacco and Cancer Program	Division of Cancer Prevention and Control National Cancer Institute, National Institutes of Health, Bethesda, MD
---------------	---	--

Analyzed data from Chinese national survey on smoking behavior. Produced research articles for publication in various journals regarding smoking behavior in China and comparisons of U.S. and Chinese smoking patterns. Laid groundwork for U.S.-China collaborative research program in smoking control. Presented papers at national and international conferences.

Since 1987	Associate Professor	Peking Union Medical College Department of Social Medicine and Public Health, Beijing, China
------------	---------------------	--

1985-1988	Attending Physician  Coordinator	National Program on Smoking and Health Ministry of Health, Beijing, China Office of National Patriotic Health Campaign Committee, Beijing, China
-----------	--	---

Coordinated national smoking control efforts, including development of provincial and local smoking control programs, support for smoking and health research projects, and "National Stop Smoking Day." Worked with the Minister of Health and other high-level health officials in coordinating the program. Wrote papers about smoking control that were published in national newspaper and magazines. Helped lay groundwork for Second National Survey on Smoking Behavior and for legislation passed in later years relating to smoking control.

1982-1985	Attending Ob/Gyn Director, Centre Research Laboratory	Department of Obstetrics and Gynecology Beijing Tongren Hospital Beijing, PR China
-----------	---	--

Led laboratory research in the experimental treatment of cancer and pre-cancerous conditions suffered by women, including the use of humic acid in the treatment of vulvar dystrophy. Continued to treat patients. Monitored treatment of patients in hospital and in clinics.

1970-1982	Obstetrics and Gynecologist	Department of Obstetrics and Gynecology Beijing Tongren Hospital, Beijing, PR China
-----------	-----------------------------	--

Clinical practice in obstetrics and gynecology.

### **Fellowships and Awards:**

- 1986-1987 World Health Organization Fellowship for studies at the University of North Carolina at Chapel Hill, School of Public Health, USA.
- 1985 Research Award for research on the clinical effects of humic acid in the treatment of vulvar dystrophy, Beijing Health Bureau, China
- 1985 Chinese Coal Ministry Grant to set up a Pharmacological Institute in study special Chinese medicines for medical use in China.

### **Professional Societies:**

Since 1992, Active Member, American Association for Cancer Research

Since 1986, Member, American Public Health Association

Since 1985, Member, Standing Committee for the Popularization of Science, Chinese Medical Association

### **Committee Responsibilities:**

- Present Graduate Student (Brandi Nicole Snyder) Advisory Committee Member, Dept. of Microbiology, Immunology & Cell Biology, WVU
- Present Graduate Student (Deanne Greene) Advisory Committee Member, Dept. of Microbiology, Immunology & Cell Biology, WVU
- 1993 Member, Preparatory Committee, The First International Academic Conference of Oriental Medicine in America
- 1990 to 1992 Co-led development of project proposal titled "Training Physicians in the People's Republic of China to Combat Tobacco Use: A U.S.-China Collaborative Developmental Trial." Investigators at American and Chinese have reviewed proposal institutions, including Peking Union Medical College (China), the US National Cancer Institute and SUNY at Buffalo. Proposal submitted in 1992 to the UICC in Geneva for funding by the President of Shanghai Medical University.
- Since 1991 Advisor, Chinese Association on Smoking and Health
- Since 1989 Consultant to the Asia-Pacific Association for the Control of Tobacco
- 1988 Consultant to the China-Finland-USA Joint Four-Disease Program and Health Education, Helsinki, Finland

- 1988 Consultant to the China-World Bank Health III Comprehensive Project in Jiangxi, Zhejiang and Shanxi Provinces, People's Republic of China
- 1987 Representative of the Ministry of Health, the People's Republic of China, at meeting of the WHO Working Group on Tobacco or Health, Tokyo, Japan

**Grant support:****Funded:**

Elsa U. Pardee Foundation

Title: Src activation of ERCC1 in ovarian cancer

PI: Daniel C. Flynn, PhD; **Co-PI: Jing Jie Yu (10%)**

7/1/2007 – 6/30/2008; Total budget: \$100,000

WV State Challenge Grant: Proteomic database for ovarian cancer

Title: Proteomics and Cancer

Goals: To establish a functional proteomics facility and to generate proteomic databases related to ovarian cancer, in collaboration with Protea Biosciences.

PI: Aaron Timperman; **Co-I: Jing Jie Yu (5%)**

9/30/2002 – 9/29/2009; Total budget: \$1,733,000;

Year 1: \$363,000

**Pending:**

MARY KAY ASH CHARITABLE FOUNDATION

Title: Src activation of ERCC1 expression and cisplatin resistance

PI: Daniel C. Flynn, PhD; **Co-I: Jing Jie Yu (10%)**

4/1/2007 – 6/30/2009; Total budget: \$115,000

NIH/RO1

Title: Gene expression-based prognosis of lung cancer recurrence

PI: Lan Guo; **Co-I: Jing Jie Yu (5%)**

1/1/2008 – 12/31/2009; Total budget: \$292,850

**Former:**

NIH/RO3: RO3 CA107979-01

Title: Biology of Chk2 Kinase in Lung Cancer

PI: Eddie Reed; **Co-I: Jing Jie Yu (27%)**

01/01/2004 – 12/31/2005

\$146,000

NIH/NCRR: RR16440-02S3A1

Title: Supplement for Cobre in Signal Transduction and Cancer

Goal: To purchase equipment to automate the WVU Proteomics facility.

PI: Daniel C. Flynn; **Co-I: Jing Jie Yu (1%)**

9/30/2003-9/29/2004

\$353,919

**Patent:**

United States Patent and Trademark Office (2-16-07): Methods for Detecting Ovarian Cancer and Anticipating Chemotherapy Response. Serial No 11/707,839.

US Provisional Patent (2006). A polymorphic variant of AFAP may predict tumor progression

US Provisional Patent (2006). Title of the Invention: AFAP Polymorphic Gene

US Provisional Patent (2003): A Novel Method of Solubilization in Subcellular Fractionation of All Cell Proteins: A Search for Biomarkers for Ovarian Cancer.

**Review Journals:**

Cancer Research  
Clinical Cancer Research

**Publications:****Journal Articles**

1. **Yu JJ.** Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy. Current Drug Therapy January, 2009.
2. **Yu JJ,** Liang XB, Yan QW, Reed E, Fojo AT, Guo Y, He Q and Mueller MD. Chk2 and ERCC1 in the DNA Adduct Repair Pathway to Acquired Cisplatin Resistance. Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. Bonetti, A.; Leone, R.; Muggia, F.; Howell, S.B. (Eds.) available February 3, 2009.
3. Hogan T, **Yu JJ,** Williams HJ, Altaha R, Liang XB and He Q. Refractory Oncocytic (Hürthle Cell) Thyroid Cancer Response to Erlotinib Human Pathology. To be submitted (2008)
4. Liang XB, Fojo AT and **Yu JJ.** Chk2 Activation by Thr-68 Phosphorylation Is Regulated by p53 in Response to Cisplatin Treatment in Human Ovarian Cancer. To be submitted (2008)
5. **Yu JJ** and Flynn DC. EGFR Artfactual Mutations Associated with two DNA Sequencers. BioTechniques, 42(1):41, 2007.
6. Yan QW, Reed E, Zhong XS, Thornton K, Guo Y and **Yu JJ.** MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochemical Pharmacology, 71:761-771, 2006.
7. Liang XB, Reed E and **Yu JJ.** Protein Phosphatase 2A Interacts With Chk2 and Regulates Phosphorylation at Thr-68 After Cisplatin Treatment of Human Ovarian Cancer Cells. Int J Mol Medicine, 17:703-708, 2006.
8. You Y, Pu P, Huang Q, Xia Z, Wang C, Wang G, Yu C, **Yu JJ,** Reed E, Li QQ. Antisense telomerase RNA inhibits the growth of human glioma cells in vitro and in vivo. Int J Oncol., 28(5):1225-32, 2006.
9. Li TY, **Yu JJ** and Reed E. Effect on cytotoxicity by blocking ERCC1 gene expression in ovarian cancer cell lines. Chinese Journal of Cancer Biotherapy, 11:92-95, 2004.

10. Yunmbam MK, Guo Y, Miller MR and **Yu JJ**. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts. Oncology Reports, 11: 833-838, 2004.
11. Li TY, Song YP, Liang XB, Guo Y, Reed E and **Yu JJ**. Confirmation of 42-bp deletion within the ERCC1 5'-UTR. International Journal of Oncology, 25:1105-1111, 2004.
12. Altaha R, Liang XB, **Yu JJ** and Reed E. Excision repair cross complementing-group 1: Gene expression and platinum resistance (Review). International Journal of Molecular Medicine, 14:959-970, 2004.
13. Reed E, **Yu JJ**, Davies A, Gannon J and Armentrout SL. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clinical Cancer Research, 9: 5299-5305, 2003.
14. **Yu JJ**, Thornton K, Guo Y, Kotz H, and Reed E. An ERCC1 splicing variant involving the 5'-UTR of the mRNA may have a transcriptional modulatory function. Oncogene, 20: 7694-7698, 2001.
15. Yunmbam MK, Li Q, Mimnaugh EG, Kayastha GL, **Yu JJ**, Jones L, Neckers L, Reed E. Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells. International Journal of Oncology, 19: 741-748, 2001.
16. Li Q, Yunmbam MK, Zhong X, **Yu JJ**, Mimnaugh EG, Neckers L and Reed E. Lactacystin enhances cisplatin sensitivity in resistant ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression. Cellular and Molecular Biology, 47, N<sup>o</sup>9, OL61-OL72, 2001.
17. **Yu JJ**, Lee KB, Mu CJ, Abernathy TV, Bostick-Bruton F, Reed E. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. International Journal of Oncology 16: 555-560, 2000.
18. **Yu JJ**, Bicher A, Ma YK, Bostick-Bruton F, Reed E. Absence of evidence for an allelic loss or allelic gain for ERCC1 and for XPD in human ovarian cancer cells and tissues. Cancer Letters, 151: 127-132, 2000.
19. Li Q, **Yu JJ**, Mu CJ, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Research, 20: 645-652, 2000.
20. Dabholkar M, Thornton K, Vionnet J, Bostick-Bruton F, **Yu JJ** and Reed E. Increased mRNA levels of XPB and CSB without increased mRNA levels of MDR1 or MT-II in platinum-resistant human ovarian cancer tissues. Biochemical Pharmacology, 60:1611-1619, 2000.
21. Reed E, Dabholkar M, Thornton K, Thompson C, **Yu JJ**, Bostick-Bruton F. Evidence for "order" in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncology Reports, 7:1123-1128, 2000.
22. **Yu JJ**, Mu CJ, Dabholkar M, Guo Y, Bostick-Bruton F, Reed E. Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. International Journal of Molecular Medicine, 1: 617-620, 1998.
23. Li Q, Ding L, **Yu JJ**, Mu CJ, Tsang B, Bostick-Bruton F, Reed E. Cisplatin and phorbol ester independently induce ERCC1 protein in human ovarian tumor cells. International Journal of Oncology, 13: 987-992, 1998.
24. **Yu JJ**, Reed EL, Mu CJ, Bostick-Bruton F, Reed E. Demonstration of a polymorphism in the gene ERCC1 by two DNA sequencing methods. Oncology Reports, 4: 905-907, 1997.

25. **Yu JJ**, Mu CJ, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutation Research Genomics, 382: 13-20, 1997.  
GenBank Acc# AF001925.
26. **Yu JJ**, Dabholkar M, Bennett WP, Welsh JA, Mu CJ, Bostick-Bruton F, Reed, E. Platinum-sensitive and platinum-resistant ovarian cancer tissues show differences in the relationships between mRNA levels of p53, ERCC1 and XPA. International Journal of Oncology, 8: 313-317, 1996.
27. Dabholkar M, Berger MS, Vionnet JA, Overton L, Thompson C, Bostick-Bruton F, **Yu JJ**, Silber JR and Reed E. Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain. Molecular Carcinogenesis, 17: 1-7, 1996.
28. **Yu JJ**, Reed E. Preliminary study of the effect of selected Chinese natural drugs on human ovarian cancer cells. Oncology Reports, 2: 571-575, 1995.
29. **Yu JJ**, Glynn T, Pechacek TF, Mueller MD, et al. The role of physicians in combating the growing health crisis of tobacco-induced death and disease in the People's Republic of China. International Journal of Health Promotion & Education, II(1): 23-30, 1995.
30. Dabholkar M, Berger MS, Vionnet JA, Egwuagu C, Silber JR, **Yu JJ** and Reed E. Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2. Cancer Research, 55: 1261-1266, 1995.
31. Dabholkar M, Vionnet J, Bostick-Bruton F, **Yu JJ**, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest., 94: 703-708, 1994.
32. Wang SQ, **Yu JJ**, Zhu BP, Liu M, He GQ. Cigarette smoking and its risk factors among senior high school students in Beijing, China, 1988. Tobacco Control, 3:107-114, 1994.
33. **Yu JJ**, Mattson ME, Boyd GM, Mueller MD, Pechacek TF, Cullen JW. A comparison of smoking patterns in the People's Republic of China with the United States: An impending health catastrophe in the middle kingdom. Journal of the American Medical Association 264 (12): 1575-1579, 1990.
34. **Yu JJ**, Mueller MD. Smoking prevalence and control efforts in China. Hygie 9(1): 22-23, 1990.
35. **Yu JJ**. Smoking and health in China. The Scientist 4(3): 9, 1990.
36. **Yu JJ**, Shopland DR. Cigarette smoking behavior and consumption characteristics for the Asia-Pacific region. World Smoking & Health 14(3):7-9, Winter 1989.
37. Lai ZG, Liang DS, Fang YR, Li WJ, Zhou J, **Yu JJ**. Quantum-chemical study of the anti-carcinogenic mechanism of hematoporphyrin. Chinese Journal of Chemistry (6):12-13, 1984.
38. **Yu JJ**, Liu ZM, Yi MG, Xu XL. Preparation of tritium-labeled fulvic acid and study of its distribution and excretion in vivo of experimental animals. Journal of Beijing Second Medical College (3):219-223, 1983.
39. **Yu JJ**, Liu ZM, Yi MG, Xu XL. Preparation of tritium-labeled fulvic acid and study of its absorption, distribution and excretion. Journal of Shanxi Humic Acid (4):54-62, 1982.
40. **Yu JJ**, Li YM, Xu XL, Jia ZY. The effects of fulvic acid on transplant tumors of mice using uptake of <sup>3</sup>H-TDR. Journal Beijing Second Medical College (1):38-40, 1982.
41. **Yu JJ**, Xu XL, Zhou J, Mu WF. Tracer experiment of whole-body autoradiography of <sup>3</sup>H-NHA in vivo of normal mice. Journal of Shanxi Humic Acid (4):51-54, 1982.
42. Yao DX, **Yu JJ**, Ye J, Zhang TH, Cui RW. Clinical report of sodium fulvate in the treatment of chronic vulvar dystrophy. Proceedings of National Conference on Medical Application and Research of Humic Acid p.95-98, December, 1982.

43. Centre Research Laboratory, Department of Pathology, Beijing Tongren Hospital; Department of Basic Science, Section of Biochemistry. The influence of sodium fulvate on plasma CAMP of rats with drug-induced hyperthyroidism and hypothyroidism. Journal of Beijing Second Medical College (2):153-156, 1981. (**Contributing author** for Centre Research Laboratory)
44. Centre Research Laboratory, Department of Internal Medicine, Beijing Tongren Hospital; Academy of Military Medicine; Institute of Chemistry, Chinese Science Academy. Treatment of acute hemorrhage of G-I tract with sodium fulvate and preliminary experimental study. Beijing Medical Journal 2(5):261-263, 1980. (**Contributing author** for Centre Research Laboratory)

### Abstracts

1. **Yu JJ**, Yan QW, Liang XB, He Q and Mueller MD. ERCC1 and Chk2 in the DNA Adduct Repair Pathway to Acquired Cisplatin Resistance. Proc Am Assoc Cancer Res, 49:abst # , 2008.
2. Liang XB, Mueller MD and **Yu JJ**. Caffeine Affects Acquired Cisplatin Resistance through DNA Adduct Repair Pathway. Proc Am Assoc Cancer Res, 49:abst # , 2008.
3. Yan QW and **Yu JJ**. Cisplatin Resistance and ERCC1 Gene Regulation. Proc Am Assoc Cancer Res, 48:abst # 4569, 2007.
4. Altaha R, **Yu JJ**, Flynn DC, Stoltzfus P, Mcewuen S, Ducatman B, Graeber G and Petros W. Evaluation of Epidermal Growth Factor Receptor Tyrosine Kinase Mutations in Patients with Primary and Metastatic Pulmonary Nodules. Proc Am Assoc Cancer Res, 48:abst # 3726, 2007.
5. Liang XB, Fojo T and **Yu JJ**. Wild Type p53 Regulates Chk2 Phosphorylation at Thr-68 in Response to Cisplatin Treatment in Human Ovarian Cancer. Proc Am Assoc Cancer Res, 48:abst # 148, 2007.
6. Yan QW, Reed E and **Yu JJ**. Activator AP1 and repressor MZF1 are key mediators in cisplatin-induced up-regulation of ERCC1 expression. Proc The 11th World Congress on Advances in Oncology and 9th International Symposium on Molecular Medicine, 18:abst # 138, 2006.
7. Yan QW, Reed E, Zhong XS, Thornton K, Guo Y and **Yu JJ**. MZF1 possesses a repressively regulatory function in ERCC1 expression. Proc Am Assoc Cancer Res, 47:abst # 1705, 2006.
8. Liang XB, Merandi J and **Yu JJ**. Expression of Selected NER Genes in Five Types of Epithelial Ovarian Cancer. Proc 9<sup>th</sup> Annual Meeting of Regional Cancer Center Consortium for the Biological Therapy of Cancer. P146, Feb 16-18, 2006.
9. **Yu JJ**, Yan QW, Guo Y and Reed E. Cisplatin regulates AP1 and MZF1 in up-regulation of ERCC1 expression. Proc 9<sup>th</sup> Annual Meeting of Regional Cancer Center Consortium for the Biological Therapy of Cancer. P133, Feb 16-18, 2006.
10. Clump D, **Yu JJ** and Flynn D. AFAP is encoded by a polymorphic gene. Proc 9<sup>th</sup> Annual Meeting of Regional Cancer Center Consortium for the Biological Therapy of Cancer. P126, Feb 16-18, 2006.
11. **Yu JJ**, Liang XB, Riedel H and Reed E. Chk2 Activation by Thr-68 Phosphorylation Is Regulated by p53 in Response to Cisplatin Treatment in Human Ovarian Cancer Cells. Proc Ovarian Cancer Symposium, p14, 2005.
12. **Yu JJ**, Liang XB, Riedel H and Reed E. Chk2 Activation by Thr-68 Phosphorylation Is Regulated by p53 in Response to Cisplatin Treatment in Human Ovarian Cancer Cells. Proc Am Assoc Cancer Res, 46:abst # 3041, 2005.

13. Liang XB, **Yu JJ** and Reed E. Protein Phosphatase 2A Interacts With Chk2 and Regulates Its Phosphorylation at Thr-68 After Cisplatin Treatment of Human Ovarian Cancer Cells. Proc Am Assoc Cancer Res, 46:abst # 5560, 2005.
14. Liang XB, Reed E and **Yu JJ**. Caffeine Enhances Cisplatin-Induced Phosphorylation of Chk 2 at Thr-68 Via Inhibition of Adenosine Receptor Signaling in Ovarian Cancer Cells. Proc Am Assoc Cancer Res, 45:abst # 2622, 2004.
15. Li TY, Wang WX, Song YP, Liang XB, Reed E and **Yu JJ**. Proof of validity of 42-bp deletion within the ERCC1 5'-UTR. Proc Am Assoc Cancer Res, 45:abst # 603, 2004.
16. **Yu JJ**, Liang XB, Song YP, Altaha R and Reed E. Expression and Alteration of the AFAP Gene in Human Ovarian Cancer Cell Lines. Proc 5<sup>th</sup> Biennial Ovarian Cancer Research Symposium - Emerging Controversies in Ovarian Cancer Research & Treatment. p137, 2004.
17. Yunbam MK, Guo Y, Reed E, Miller MR and **Yu JJ**. The antineoplastic product harringtonine increases cisplatin-DNA adducts and alters p53 expression in ovarian cancer cells. Proc Am Assoc Cancer Res, 44 (2<sup>nd</sup> edition):abst # R4040, 2003.
18. **Yu JJ**, Flynn DC, Song YP, Liang XB and Reed E. A Novel Method of Solubilization in Subcellular Fractionation of Detergent-Soluble and -Insoluble Fractions: A Search for Biomarkers for Ovarian Cancer. Clinical Cancer Research 2003.
19. **Yu JJ**, Flynn DC, Song YP, Liang XB and Reed E. A Novel Method of Solubilization in Subcellular Fractionation of Detergent-Soluble and -Insoluble Fractions: A Search for Biomarkers for Ovarian Cancer. Proc AACR-NCI-EORTC, abst #882, 2003.
20. **Yu JJ**, Trostel S, Gor N and Reed E. E-box motif(s) in the 5'-UTR of the human ERCC1 gene may be functionally involved in a 42-bp splicing-deletion. Proc AACR-NCI-EORTC, abst # 670, 2001.
21. **Yu JJ**, Thornton K, Guo Y, Zhong XS, Bostick-Bruton F and Reed E. A specific 42 bp deletion in Exon 1 of the ERCC1 gene is associated with increased mRNA expression in human ovarian cancer tissues. Proc Am Assoc Cancer Res, 41:abst # 5506, 2000.
22. Slavsky D, Cong H, **Yu JJ**, Jones L, Bostick-Bruton F, Reed E. Clear cell carcinoma of the ovary shows higher mRNA levels of ERCC1 and of XPB as compared to other histological types of epithelial ovarian cancer. Proc Am Assoc Cancer Res, 40: abst # 4438, 1999.
23. Cong H, Slavsky D, **Yu JJ**, Jones L, Bostick-Bruton F, Reed E. Comparative assessment of mRNA levels of ERCC1 and XPB in matched malignant and non-malignant tissues from patients with epithelial ovarian cancer. Proc Am Assoc Cancer Res, 40: abst # 4437, 1999.
24. Slavsky D, **Yu JJ**, Cong H, Reed E. Concordance of XPB mRNA expression in malignant and non-malignant tissues from patients with human ovarian cancer. Proc Am Assoc Cancer Res, 39:632, abst # 4299, 1998.
25. Cong H, **Yu JJ**, Slavsky D, Reed E. Concordance of ERCC1 mRNA expression in malignant and non-malignant tissues from patients with human ovarian cancer. Proc Am Assoc Cancer Res, 39:632, abst # 4300, 1998.
26. **Yu JJ**, Mu CJ, Dabholkar M, Bostick-Bruton F, Reed E. Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines. Proc Am Assoc Cancer Res, 38:449, abst # 3005, 1997.
27. **Yu JJ**, Dabholkar M, Bostick-Bruton F, Reed E. Nucleotide excision repair and human ovarian cancer. National Cancer Institute, Comprehensive Minority Biomedical Program (CMBP) Clinical, Poster 32, 1996.

28. **Yu JJ**, Mu CJ, Lee KB, Okamoto A, Bostick-Bruton F, Mitchell KC, Reed E. A silent mutation in nucleotide excision repair ERCC1 gene in human ovarian cancer cell lines and tumor tissues. Proc Am Assoc Cancer Res, 37:549, abst # 3762, 1996.
29. Lee KB, **Yu JJ**, Abernathy T, Stewart AB, Okamoto A, Bostick-Bruton F, Reed E. Cisplatin-DNA adduct repair in a human ovarian (OvCa) cancer cell line, MCAS, with a silent mutation of ERCC1. Proc Am Assoc Cancer Res, 37:554, abst # 3795, 1996.
30. Dabholkar M, Vionnet J, Bostick-Bruton F, **Yu JJ**, Reed E. Nucleotide excision repair (NER) mediates clinic resistance to platinum compounds in human ovarian cancer. Proc Am Assoc Cancer Res, 36:217, abst # 1295, 1995.
31. Bostick-Bruton F, Dabholkar M, Silber J, **Yu JJ**, Berger M, Reed E. Measurement of p53 mRNA levels in malignant and non-malignant human brain tissues. Proc Am Assoc Cancer Res, 36:230, abst # 1370, 1995.
32. **Yu JJ**, Dabholkar M, Vionnet JA, Bostick-Bruton F, Reed E. p53, XPAC, and ERCC1 expression in fresh human ovarian cancer tissues. Proc Am Assoc Cancer Res, 35:180, abst # 1076, 1994.
33. Dabholkar M, Berger M, Silber J, Vionnet JA, **Yu JJ**, Reed E. Expression levels of the DNA excision repair genes ERCC1, XPAC, and ERCC2, in malignant and non-malignant brain tissues. Proc Am Assoc Cancer Res, 35:226, abst # 1352, 1994.
34. **Yu JJ**, Reed E. Preliminary study of the effect of selected Chinese herbal medicine on human ovarian cancer cells. The First International Academic Conference of Oriental Medicine in America, Flushing, New York, p13, 1993.
35. Dabholkar M, Vionnet J, Bostick-Bruton F, **Yu JJ**, Reed E. Alternative splicing of ERCC1 mRNA in human ovarian cancer tissues. New York Academy of Sciences. DNA damage: Effects on DNA structure and protein recognition. Burlington, Vermont, # p30, 1993.
36. Dabholkar M, **Yu JJ**, Parker RJ, Lee KB, Bostick-Bruton F, and Reed E. Effect of taxol and cisplatin treatment on the expression of excision repair genes in human ovarian cancer cells. Proc Am Assoc Cancer Res, 34:357, abst # 2127, 1993.
37. **Yu JJ**, Mattson ME, Boyd GM, Mueller MD, Pechacek TF, Cullen JW. A comparison of smoking patterns in the People's Republic of China with the United States: An impending health catastrophe in the middle kingdom. in The 1991 Yearbook of Pulmonary Disease, p 208-209, 1991.
38. **Yu JJ**, Xu XL, Liu ZM, Yi MG. Preparation of tritium-labeled fulvic acid and study of its absorption, distribution and excretion. Chinese Journal of Physiological Sciences (Section of Biochemistry and Molecular Biology) 3(1): p. 52, 1983.
39. **Yu JJ**, Liu ZM, Yi MG, XU XL. Preparation of tritium-labeled fulvic acid and study of its absorption, distribution and excretion. Proceedings of National conference on Medical Application and Research of Humic Acid p.83-84, December, 1982.

#### **Additional Articles**

1. **Yu JJ**. Quit for you and others, please. Chinese Women p.3, February, 1988.
2. **Yu JJ**. Review of tobacco and smoking cessation methods. Chinese People's Daily p.5, March 23, 1988.
3. **Yu JJ**. Smoking and tobacco: A serious problem in China. Chinese Provision p.1, April, 1988.
4. **Yu JJ**. Worldwide anti-smoking campaigns. Chinese Health Consultation p.2, April, 1988.

5. **Yu JJ.** Smoking free society. *Outlook Weekly* (14): 4, 1988.

### **Seminar and Symposia Presented:**

1. Oral Presentation at the X<sup>th</sup> International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy: ERCC1 and Chk2 in the DNA Adduct Repair Pathway to Acquired Cisplatin Resistance. Verona, Italy, Nov. 30<sup>th</sup> to Dec. 3<sup>rd</sup> 2007.
2. Presented and Chaired a session at 11th World Congress on Advances in Oncology and 9th International Symposium on Molecular Medicine: Activator AP1 and repressor MZF1 are key mediators in cisplatin-induced up-regulation of ERCC1 expression, Crete, Greece, October, 2006.
3. Chk2 Activation by Thr-68 Phosphorylation Is Regulated by p53 in Response to Cisplatin Treatment in Human Ovarian Cancer Cells. AACR 96<sup>th</sup> Annual Meeting, Anaheim, Orange County, CA, 2005.
4. Protein Phosphatase 2A Interacts With Chk2 and Regulates Its Phosphorylation at Thr-68 After Cisplatin Treatment of Human Ovarian Cancer Cells. AACR 96<sup>th</sup> Annual Meeting, Anaheim, Orange County, CA, 2005.
5. New Core Facility of Molecular Medicine and Screening for Mutations in Lung Cancer. MBRCC Annual Retreat, Stonewall Resort, WV, 2005.
6. p53 Mutational Spectrum in Human Ovarian Cancer Cell Lines and Tumor Tissues. Oncotech Research Inc., Irvine, CA, 2004.
7. Combinatorial treatment of ovarian cancer cells with harringtonine and cisplatin results in increased cisplatin-DNA adducts. Department of Biochemistry and Molecular Pharmacology, WVU, Morgantown, WV, 2004.
8. Caffeine Enhances Cisplatin-Induced Phosphorylation of Chk2 at Thr-68 Via Inhibition of Adenosine Receptor Signaling in Ovarian Cancer Cells. AACR 95<sup>th</sup> Annual Meeting, Orlando, FL, 2004.
9. Proof of validity of 42-bp deletion within the ERCC1 5'-UTR. AACR 95<sup>th</sup> Annual Meeting, Orlando, FL, 2004.
10. Expression and Alteration of the AFAP Gene in Human Ovarian Cancer Cell Lines. 5<sup>th</sup> Biennial Ovarian Cancer Research Symposium - Emerging Controversies in Ovarian Cancer Research & Treatment. Seattle, WA, 2004.
11. An Overview of Use of Traditional Asian Medicine. 123rd Annual Meeting of the American Public Health Association, San Diego, CA, October 29-November 2, 1995.
12. p53 Mutational Spectrum in Human Ovarian Cancer Cell Lines and Tumor Tissues. Oncotech Research Inc., Irvine, CA, November 1, 1995.
13. The Effect of Harringtonine on Human Ovarian Cancer Cells. 123rd Annual Meeting of the American Public Health Association, San Diego, CA, October 29-November 2, 1995.
14. Preliminary Study of the Effect of Chinese Medicinal Herbs on Human Ovarian Cancer Cells. The First International Academic Conference of Oriental Medicine in America Flushing, New York, July 2-4, 1993.
15. A Comparison of Smoking Patterns in the People's Republic of China With the United States. The Eighth World Conference on Tobacco or Health, Buenos Aires, Argentina, March 30-April 3, 1992.

16. The Role of Physicians in Combating the Potential Tobacco Pandemic in China. The Eighth World Conference on Tobacco or Health, Buenos Aires, Argentina, March 30 - April 3, 1992.
17. An Overview of Health Needs of Asian-American Women and Children 120th Annual Meeting of the American Public Health Association, Washington, DC, November 8-12, 1992.
18. Chronic Disease Control in the People's Republic of China. 120th Annual Meeting of the American Public Health Association, Washington, DC, November 8-12, 1992.
19. An Overview of the Role of Traditional Chinese Medicine in Health Promotion and Disease Prevention in China. 119th Annual Meeting of the American Public Health Association, Atlanta, GA, November 10-14, 1991.
20. ZBA and ZAH: Two New Chinese Herbal Medicines for AIDS. 119th Annual Meeting of the American Public Health Association, Atlanta, GA, November 10-14, 1991.

### Teaching:

- Since 2001 Providing 16 hours of conference teaching in Medical Pharmacology (Course No: PCOL 761) in Department of Biochemistry & Molecular Pharmacology, WVU.
- Fall 2005 Providing one hour each lecture teaching in Pathology (Course No: 751) and in Basic and Clinical Aspects of Neoplasia (Course No: CCMD793) in Department of Pathology and in Mary Babb Randolph Cancer Center, WVU.
- 2001-3/2005 Trained and supervised young scientists to conduct molecular genetic research in the laboratory of Cancer Center Director at WVU MBRCC, Morgantown, WV
- 1993-1/2001 Trained laboratory personnel (graduate students, post-doctoral staff, physicians), Medical Ovarian Cancer Section, Medicine Branch, Division of Clinical Sciences National Cancer Institute, National Institutes of Health, Bethesda, MD
- 1982-1988 Clinical Research Lecture Series, Beijing Tongren Hospital. Subjects: Alternative and experimental treatment of cancer and pre-cancerous conditions suffered by women; Applications of novel and natural medicine, including humic acid in the treatment of vulvar dystrophy.

### List of Trainees:

<u>Name &amp; Degree</u>	<u>Training Level &amp; Duration</u>	<u>Current Position</u>
Ramin Altaha, M.D.	Techniques in DNA damage and repair pathway (Translational study) 6 months	Assistant Professor Section of Hematology/Oncology Mary Babb Randolph Cancer Center West Virginia University
Troy V. Abernathy B.S., M.S.	The effect of ERCC1 polymorphism on drug resistance & DNA repair in ovarian cancer cell lines (Master's level) 2 years	Medical Student, Wake Forest University, School of Medicine, Winston Salem, NC

Marycharmain Belcastro B.A.	HPV and cervical cancer: Induction of IMIQUIMOD in C/EBP- $\beta$ gene expression (Bachelor's level) 6 months	Research Assistant, Dept. Ob/Gyn, WVU School of Medicine, Morgantown, WV
Hong Cong M.D.	DNA repair gene, ERCC1 expression in human ovarian cancer tissues by RT-PCR & southern hybridization (Master's level) 2 years	Self-employed, Rockville, MD
Neelam Gor B.S.	Study of transfectional factor RFX-1 by PCR & southern hybridization (Bachelor's level) 2 years	Medical student, GWU School of Medicine, Washington, DC
Yi Guo B.S.	Herbal medicine studies in human cancer by RT-PCR & DNA sequence analysis (Bachelor's level) 1 year	Contract Chemist, Dupont Pharmaceuticals, Newark, DE
Percy Julian	Tissue culture and RNA isolation in ovarian cancer cell lines (Undergraduate level) 2 years	College student, Princeton University, Princeton, NJ
Ganesh Kayastha B.S.	NER and related gene expression by western blot analysis (Bachelor's level) 2 years	Cancer Research Training Award (CRTA) Experimental Therapeutics Section, Cancer Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD
Herb Kotz M.D.	NER expression & deletion in human ovarian cancer (Translational study training) 1 year	Ob/Gyn Volunteer, Medical Ovarian Cancer Section Medicine Branch, NCI, NIH Bethesda, MD
Yun Kun Ma M.D., Ph.D.	NER gene-copy number in human ovarian cancer specimens by western blot analysis (Post-doctoral level) 2 years	Database Administrator, Zona Financiera.Com, Fairfax, VA 22031
Kimberly C. Mitchell B.A., M.P.H.	Detection of ERCC1 polymorphism in ovarian cancer cells & tissues (Master's level) 1 year	Assistant Coordinator, National Sids & Infant Death Program Center, Baltimore, MD

Chuanjie Mu M.D.	Detection of NER gene mutation by SSCP & DNA sequencing (Post-doctor's level) 2 year	Professor, Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Tianjin China
Aikou Okamoto M.D., Ph.D.	Mechanism of drug resistant phenotype in ovarian cancer targeting cell cycle genes, including p53, P16 & p18 (Post-doctor's level) 6 months	Gynecologist, Dept. Ob/Gyn, School of Medicine, Tokyo Jikei University
Tessla M. Pitman	PCR technology in VEGF & c-Jun expression (undergraduate level) 3 months	College Student, Shepherd College, Shepherdstown, WV
Daniel Svlaskey B.A	DNA repair gene, XPB expression in human ovarian cancer tissues by RT-PCR & southern hybridization (Master's level) 2 years	Dental Student, Tufts University, Dental School, Boston, MA
Shana Trostel B.A.	ERCC1 deletion in human normal & tumor tissues by northern hybridization & DNA sequencing (Bachelor's level) 2 years	Biologist, Experimental Therapeutics Section, Cancer Therapeutics Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD
Tiyuan Li Ph.D.	WVU Postdoctoral fellow (2002-2003)	Director, Center of Clinical Research Shen-Zhen People's Hospital, China
Wendy Virtue B.S.	WVU Graduate student (2003)	Protea Biosciences, Inc. MBRCC Morgantown, WV
Matt Phillips B.S.	WVU Research assistant (2003-2004)	Sr. Radiation Safety Specialist, HSC Radiation Safety, WVU
Yuping Song M.S.	WVU Research Instructor (2005)	WVU MBRCC Core Facility of Molecular Medicine
Jenna Merandi (Undergraduate level)	Lab technique of Molecular Medicine (2005-2006)	WVU School of Pharmacy
Qi He M.D., M.S.	WVU Postdoctoral fellow (2006)	University of Chicago Chicago, IL
Kristina Bacon (2006 WV-INBRE)	Pharmacokinetics/Molecular Biology Studies (2006-2007)	Wheeling Jesuit University WV

John-Paul Jansen M.D.	PCR & DNA Sequencing Technique (2007)	WVU School of Medicine
Jillian Lee Rogers Medical Student	Gene Expression Technique (Summer, 2007)	WVU School of Medicine
Elyse Lindsey Walk Graduate Student	Gene Expression Technique (Fall, 2007)	WVU MBRCC
Xiaobing Liang M.D.	WVU Postdoctoral fellow (2002-present)	WVU MBRCC Molecular Medicine Core
Honglan Zhu M.D.	WVU Postdoctoral fellow (February 2008)	WVU MBRCC Molecular Medicine Core
Lance Parker Shinn Undergraduate level	Course Requested Training (Summer, 2008)	WVU Biology Department